BMO Capital Initiates Coverage On MapLight Therapeutics with Outperform Rating, Announces Price Target of $46
Benzinga Newsdesk 3 months ago
Analyst RatingsNewsInitiationPrice Target
BMO Capital analyst Malcolm Hoffman initiates coverage on MapLight Therapeutics (NASDAQ:MPLT) with a Outperform rating and announces Price Target of $46.
BMO Capital analyst Malcolm Hoffman initiates coverage on MapLight Therapeutics (NASDAQ:MPLT) with a Outperform rating and announces Price Target of $46.